Navigation Links
WellPoint Reports First Quarter 2009 Results
Date:4/22/2009

-- Net income was $1.16 per share, including net realized investment losses of $0.46 per share, 8 percent higher than in the first quarter of 2008

-- Operating cash flow totaled $1.2 billion

-- Full year 2009 net income now expected to be in the range of $5.14 - $5.20 per share, including net realized investment losses of $0.46 per share

-- Insurance subsidiaries remain well-capitalized with statutory capital levels approximately $5.5 billion above state regulatory levels and $2.3 billion above Blue Cross and Blue Shield requirements

INDIANAPOLIS, April 22 /PRNewswire-FirstCall/ -- WellPoint, Inc. (NYSE: WLP) today announced that first quarter 2009 net income was $580.4 million, or $1.16 per share, including net realized investment losses of $228.4 million after-tax, or $0.46 per share. Net income in the first quarter of 2008 was $588.1 million, or $1.07 per share, which included net realized investment losses of $0.06 per share.

"Our first quarter was solid in light of the current economy, and it is clear that the performance improvement initiatives we put into place last year are generating positive results," said Angela F. Braly, president and chief executive officer of WellPoint, Inc. "While our membership levels have been impacted by employer workforce reductions, we continue to take action to make our products more attractive and create more value for our customers."

"We are pleased that, despite the economy, our enrollment in the National business increased by more than 400,000, or 3.6 percent, during the quarter. This is an indication that our value proposition remains market-leading, with the industry's broadest provider network, attractive discounts and excellent medical management services. We look forward to our new strategic alliance with Express S
'/>"/>

SOURCE WellPoint, Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Express Scripts Announces Definitive Agreement to Acquire WellPoint NextRx Subsidiaries for $4.675 Billion
2. Charles Kennedy, M.D., Vice President for Health Information Technology, WellPoint, Inc., Appointed to National Health I.T. Policy Committee
3. AMA Announces Physician Class Action Against WellPoint
4. WellPoint Announces Strategic Relationship With Availity to Enhance the Provider and Health Plan Relationship and Advance Improvements in Patient Care
5. WellPoint Named to DiversityIncs 2009 DiversityInc Top 50 Companies for Diversity(R)
6. WellPoint Announces Appearances at Upcoming Conferences
7. WellPoint Foundation Awards Grants to OASIS to Expand Unique Active Generations Program
8. WellPoint Highlights Operational Accomplishments and Details 2009 Guidance at Annual Investor Meeting
9. WellPoint Announces Appearance at 2nd Annual Medicaid Managed Care Summit
10. National Coalition for Cancer Survivorship, UCLA, WellPoint, and Genentech Launch Initiative to Provide Coordinated Follow-Up Care for People Surviving Cancer
11. WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , Dr. Redlener Applauds Historic Effort b...et Programs Are Lost in Final Health Care Reform ... The New England Journal of Medicine today pub...th care reform, co-authored by Irwin Redlener, M.D... National Center for Disaster Preparedness and Pro...
(Date:12/4/2009)...with knowledge of risks, many hesitate to take bre... Dec. 4 (HealthDay News) -- Worries about side eff...ican women at high risk for breast cancer are will...ase, a new study finds. , In an effort to infor... researchers at the University of Michigan Compreh...
(Date:12/4/2009)... , BOULDER, Colo., Dec. 4 ..., ON LOVE ,, Kathryn Budig, a prominent yoga te...e to healing--with a viewing of Twilight,s New Moo...nal.com: ,, http://www.elephantjournal.com/200...ournal.com: TASHI KING AND BREAST CANCER ,, el...
(Date:12/4/2009)... , JEFFERSON CITY, Mo., Dec. 4 /PRNewswire/ ...ctor Paul Crosetti, State Fire Marshal Randy Cole,...en,s fire safety program sponsored by Farmers call... safety day at the Missouri Capitol December 9. .../20080605/LATH062 ) ,, "The call for fire safet...
(Date:12/4/2009)...le who have had an ischemic stroke are at higher l... of medication can reduce that risk. One of the si...s, otherwise known as blood thinners, of which the...tudy to determine whether the use of antithromboti...r a seven-year period found that in each of the ye...
Breaking Medicine News(10 mins):Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Missouri Safety Day at the Capitol 2Health News:Are stroke survivors taking their medicine? 2
..., Dec. 3 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP...igational new,drug (IND) application to the U.S. F...und is an internally developed, orally-bioavailabl...r,patients in early 2008., "This IND submission i...
... N.Y., Dec. 3 Big A Drug Stores, Inc. has,selecte...al estate,solutions, to exclusively manage the dis...California. Big A Drug Stores, Inc. is a chain of ...gs,","Drug Fair," and "Drug Barn" (2 stores)., "W...
...APOLIS Although more and more drug advertisements...oximately $21 billion dollars that pharmaceutical ...is targeted to physicians, doctors in training (re...c. published in the December issue of the journal ...
...and PITTSBURGH, Dec. 2 Forest,Laboratories, Inc. ...ed that,Mylan has received an approvable letter fr...response to its New Drug Application (NDA) for,neb...icated that a recent inspection of,a backup manufa...
... communication with doctors and respect for role o...Y, Dec. 2 (HealthDay News) -- The death of a child...dparents, siblings, friends, even the child,s doct...ymptoms and stress of life-threatening illness -- ...
...ESTER, Ill. Hospital staff nurses who work extend...at work, or obtain less sleep are more likely to e... study published in the December 1 issue of the jo...ed from 895 full-time hospital staff nurses, who c...
Other Medicine News:Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 2Health News:SGX Pharmaceuticals Submits Investigational New Drug Application for SGX523, a Highly Potent, Selective, Orally Bioavailable cMET Inhibitor 3Health News:Big A Drug Stores, Inc. Retains DJM Realty to Dispose of All Stores Operating Under the Names of Drug Emporium, Big A, Camelot, Drug Fair and Drug Barn 2Health News:Do medical schools affect the way future doctors interact with drug companies? 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 2Health News:FDA Issues Approvable Letter for Nebivolol for the Treatment of Hypertension 3Health News:Breaking Down Barriers to End-of-Life Care for Children 2Health News:Breaking Down Barriers to End-of-Life Care for Children 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 2Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 3Health News:Nurses working extended shifts, are tired at work and sleep little likely to drive drowsy 4
(Date:12/4/2009)..., , BETHESDA, Md., Dec. 4 Dr...lts for prostate-specific antigen (PSA) recurrence...nts of biochemical recurrence rate in a Phase III ... for injection) or monthly leuprolide in prostate .... Prostate cancer patients who received FIRMAGON ...
(Date:12/3/2009)..., , NEW YORK, Dec. 3 Guid...rm, today announced the launch of their Sleep Apne...t monitors and projects trends and market share in...p Apnea Tracker captures actual patient usage for ...nited States from 15 different equipment providers...
(Date:12/3/2009)..., , SUNNYVALE, Calif., Dec. 3 /PRNewswire-..., a biopharmaceutical company focused on developin...ugs for the treatment of immune mediated diseases ...bcast and conference call on, Tuesday, December 8,...e and 8:00am Pacific Time) to discuss clinical dat...
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Leading Primary Research Firm Guidepoint Global Announces Launch of Sleep Apnea Tracker 2Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 1Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 2Pearson Announces Leah Jewell as President of Health Science and Careers Division 55714 3ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 1ReBuilder Medical Technologies Inc s Dr Phillips to Speak to Ohio Investment Group 55711 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 1CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 2CriticalPoint 28TM 29 Launches Seven New Virtual Compounder 28TM 29 Training Modules 55708 3
...nc., a privately held biopharmaceutical company th...mmercialization of prescription ophthalmic pharmac... safety and efficacy results from the first human ...luocinolone acetonide (FA) intravitreal insert) wi...ion for Research in Vision and Ophthalmology (ARVO...
...President and Chief Executive Officer of Smithfiel...pdate to all employees on the progress of the test... in Veracruz: , , To Our Employees: , , The medi...outbreak on a minute-to-minute basis, and while we...ut the day-to-day status of the testing being cond...
Other Medicine Technology:Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting 2Smithfield Sends Update to Employees on Testing Process at Veracruz Joint Venture 2
HOME MULTI-DRUG TEST
SEDIPLAST ESR SYSTEM (with diluent)
SEDIPLAST ESR SYSTEM (without diluent)
Hemaprompt FG Gastric and Fecal Occult Blood Test
Medicine Products: